Company Overview and News

 
Limelight Networks: No Longer Flying Under The Radar

2018-09-07 seekingalpha
LLNW has four solid quarters under its belt and is expectedto average 46% earnings growth over the next three years.
LLNW

130
The 7 Best Penny Stocks to Buy

2018-08-08 investorplace - 1
Penny stocks are often dangerous for individual investors. Generally described as stocks with a price under $5, the group usually consists of quite a few fallen angels and growth stocks that haven’t reached, and potentially won’t reach, their potential.
ICON STZ.B FB DHXM XOM CHKVP NFLX PIR CHKDH CHKVZ WMT CHKDG LLNW CHKDJ AMZN CHKDP CCJ PLUG ROX DEO AKAM CKRGZ FDX STZ CHKWZ DHX.A CHK CHK.WI DMQHF SNE HTZ SPWH

 
Limelight Networks (LLNW) Catches Eye: Stock Jumps 9.6%

2018-07-23 zacks
Limelight Networks, Inc. (LLNW - Free Report) was a big mover last session, as the company saw its shares rise nearly 10% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. The stock picked up sharply from the near-flat trend of $4.46 to $4.85 in the past one month time frame.
LLNW ATHM

 
LLNW / Limelight Networks, Inc. 10-Q (Quarterly Report)

2018-07-20 sec.gov
Document Table of Contents
LLNW

1
Limelight Networks, Inc. (LLNW) CEO Robert Lento on Q2 2018 Results - Earnings Call Transcript

2018-07-20 seekingalpha - 1
Good day, ladies and gentlemen. Welcome to the Limelight Networks 2018 Second Quarter Financial Results Conference Call. At this time, all participants are in a listen-only mode. At the end of the prepared remarks, we will provide instructions for those interested in entering the queue for the question-and-answer session. I would now turn the call over to Dan Boncel, Limelight's Chief Accounting Officer.
LLNW

7
LLNW / Limelight Networks, Inc. 8-K (Current Report)

2018-06-11 sec.gov - 1
Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION
LLNW

6
Here’s one simple solution to helping Americans manage their money - MarketWatch

2018-06-08 marketwatch
Few schools teach financial literacy, but there could be another way for Americans to learn this crucial knowledge.
LLNW

28
B. Riley Financial's (RILY) CEO Bryant Riley on Q1 2018 Results - Earnings Call Transcript

2018-05-07 seekingalpha - 2
B. Riley Financial, Inc. (NASDAQ:RILY) Q1 2018 Results Earnings Conference Call May 7, 2018 4:30 PM ET
LLNW BONTQ BEBE RILY SCC 3772 BONT UNTD SRSCQ SRSC

18
Cramer Remix: Apple could have just signaled a Trump-China trade deal

2018-05-02 cnbc
One month ago, Facebook seemed to be on the brink of demise, with CEO Mark Zuckerberg testifying before Congress about a data-harvesting scandal that affected millions of users.
LLNW TXN UNH COUP

29
Cramer's lightning round: Danaher is one of my favorite trust holdings

2018-05-02 cnbc
Danaher: "OK, Danaher's one of the most well-managed companies in the country. I tell club members of ActionAlertsPlus.com [that] this may be the finest company we own in the entire portfolio of the charitable trust right here, right now. Did you see they're trying to buy the $20 billon life science division of GE? [That] made me feel like maybe, indeed, GE is done going down."
LLNW GIS TXN STX GWP

13
CatchMark Timber Trust started at sector perform with $14 stock price target at RBC Capital

2018-05-02 marketwatch
CatchMark Timber Trust Inc (CTT) Files 10-K for the Fiscal Year Ended on December 31, 2017
LLNW CTT GPN TTS CRL

6
LLNW / Limelight Networks, Inc. null

2018-04-28 sec.gov
begin 644 filename1.pdf M)5!$1BTQ+C4-"B6UM;6U#0HQ(# @;V)J#0H\/"]4>7!E+T-A=&%L;V7!E+U!A9V5S+T-O=6YT(#$O2VED7!E+T=R;W5P+U,O5')A;G-P87)E;F-Y M+T-3+T1E=FEC95)'0CX^+U1A8G,O4R]3=')U8W1087)E;G1S(# ^/@T*96YD M;V)J#0HT(# @;V)J#0H\/"]&:6QT97(O1FQA=&5$96-O9&4O3&5N9W1H(#(S M,C4^/@T*
LLNW

7
LLNW / Limelight Networks, Inc. null

2018-04-28 sec.gov - 1
CORRESP Limelight Networks, Inc. 222 South Mill Avenue, 8th Floor Tempe, AZ 85281 VIA EDGAR AND FACSIMILE
LLNW

7
LLNW / Limelight Networks, Inc. DEF 14A

2018-04-27 sec.gov - 1
Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION
LLNW

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

2018-09-18 - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...

CUSIP: 53261M104